News

Number of news items returned: 21 to 40 records of 411

Guarda's Enviro Chasing Services update

09 May 2018

(3769 views)

Guarda Group Holdings' MD, Craig, Penty, provides this update: "We have been lobbying government in WA for a number of years ...

Dealer Trade goes from strength to strength

30 April 2018

(4526 views)

  Dealer Trade Holdings announced that its subsidiary CarRecord has entered into a partnership with Gumtree. Since the integration in late ...

Breakfast Invitation, Lessons and News - Funding Strategies Connect April 2018

30 April 2018

(4198 views)

  Breakfast Invitation, Lessons and News - Funding Strategies Connect April 2018   Dear Readers, Welcome to the April 2018 edition of Funding Strategies ...

Mark's lessons on capital raising

27 April 2018

(4624 views)

  Mark's lessons on capital raising: Make sure material arrangements are supported by appropriate documentation; Be flexible on how the investment might be ...

Guarda Group signs up major clients

26 April 2018

(4566 views)

  "Guarda Group signs up major clients   On behalf of Guarda Group Holdings, I am delighted to announce that our Perth based ...

Queensland Small Business Week 2018 - Breakfast

19 April 2018

(4765 views)

Queensland Small Business Week 2018 - Breakfast As part of Queensland Small Business Week 2018, Dr Mark Rainbird and his team ...

OpenPort Announces the Launch of the OEL Foundation to Promote Blockchain Innovation within the Supply Chain Industry

19 April 2018

(4298 views)

"OpenPort Announces the Launch of the OEL Foundation to Promote Blockchain Innovation within the Supply Chain Industry   Hong Kong – April 19, ...

"OpenPort actively seeking investors for blockchain transport technology reverse takeover - CEO"

12 April 2018

(5042 views)

  "OpenPort actively seeking investors for blockchain transport technology reverse takeover - CEO OpenPort, a Hong Kong-based global blockchain transport management technology ...

AqMB Holdings - Director Briefing with Darren Szczepanski

10 April 2018

(5520 views)

  In this Director Briefing, Darren Szczepanski, Managing Director of AqMB Holdings Pty Ltd (AqMB Holdings, the Company) discusses: Innovative water treatment ...

"Cyber Research turns down buyers to build more value ahead of potential exit - CEO"

10 April 2018

(5092 views)

  "Cyber Research turns down buyers to build more value ahead of potential exit - CEO Cyber Research, a private Brisbane, Australia-based ...

"Copper supply crunch earlier than predicted — experts"

10 April 2018

(348 views)

"Copper supply crunch earlier than predicted — experts   Copper demand will surpass supply earlier than expected, with the first clear ...

"Copper pipeline lowest in a century"

06 April 2018

(334 views)

"Copper pipeline lowest in a century   Appetite for copper-mining assets is picking up after prices climbed in 2017 to the highest ...

"AqMB Holdings ramping up water solutions software revenue ahead of potential trade sale from 2020 - MD"

05 April 2018

(4745 views)

  "AqMB Holdings ramping up water solutions software revenue ahead of potential trade sale from 2020 - MD   AqMB Holdings, a privately ...

"Supply Chain Inefficiencies In Emerging Markets: Is Blockchain The Answer?"

28 March 2018

(4896 views)

"Supply Chain Inefficiencies In Emerging Markets: Is Blockchain The Answer?   By Max Ward, CEO and Founder of OpenPort Emerging markets represent the ...

"Blockchain In Transit: OpenPort Paves New Road to Shipping Traceability and Transparency"

27 March 2018

(5054 views)

  Diamond-Michael Scott Digital Economy Journalist Specializing in Blockchain Technology| Fueling The Advancement of Freedom Through Technology "Blockchain In Transit: OpenPort Paves New ...

OpenPort

20 March 2018

(5495 views)

"Canoe Mining Enters Reverse-Takeover LOI with OpenPort, a Private Placement and Disposition of Assets   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ...

Easter, Event, Introductions and News - Funding Strategies Connect March 2018

16 March 2018

(5188 views)

    Easter, Event, Introductions and News - Funding Strategies Connect March 2018   Dear Reader, Welcome to Funding Strategies Connect. We have seen a ...

JNCI publication involving CytImmune's CYT-21625

10 March 2018

(5452 views)

  "JNCI publication involving CytImmune's CYT-21625"   "Please find attached [via the link below] an article published in the most recent version of ...

AqMB introduces SupplierLink

08 March 2018

(5283 views)

  AqMB introduces SupplierLink   "Welcome to your virtual marketplace Process designers are busy people. Conferences and trade shows are expensive and the leads ...

"APRA to introduce first prudential standard aimed at tackling growing threat of cyber attacks"

07 March 2018

(5405 views)

"APRA to introduce first prudential standard aimed at tackling growing threat of cyber attacks"   Cyber Research has advised us of another ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625